表紙
市場調査レポート

エボラウイルス感染症:パイプライン分析

Ebola Viral Infections - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 264102
出版日 ページ情報 英文 282 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
エボラウイルス感染症:パイプライン分析 Ebola Viral Infections - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 282 Pages
概要

エボラウイルス感染症は、人体の内外で出血が生じるという、難病かつ死病と言える疾患です。主な徴候・症状として、発熱や重い頭痛、関節痛・筋肉痛、喉の痛み、吐き気・嘔吐、下痢、胸痛、咳などが挙げられます。主な治療法には、酸素療法や輸血、経静脈(IV)輸液、鎮痛剤などがあります。

当レポートでは、世界各国でのエボラウイルス感染症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

エボラウイルス感染症の概要

治療薬の開発

  • エボラウイルス感染症向けパイプライン製品:概要
  • エボラウイルス感染症向けパイプライン製品:比較分析

各企業で開発中のエボラウイルス感染症治療薬

大学/研究機関で研究中のエボラウイルス感染症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

エボラウイルス感染症治療薬:開発中の製品の一覧(企業別)

エボラウイルス感染症治療薬:研究中の製品の一覧(大学/研究機関別)

エボラウイルス感染症治療薬の開発に従事している企業

  • Abivax S.A.
  • AnGes MG, Inc.
  • ANP Technologies, Inc.
  • Arno Therapeutics, Inc.
  • Avipero Limited
  • BioCryst Pharmaceuticals, Inc.
  • BioFactura, Inc.
  • Celgene Corporation
  • Emergent BioSolutions Inc.
  • Enyo Pharma S.A.S.
  • Etubics Corporation
  • GeoVax Labs, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Globavir Biosciences, Inc.
  • Hemispherx Biopharma, Inc.
  • Humabs BioMed SA
  • Immune Response BioPharma, Inc.
  • Immunovaccine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Integrated BioTherapeutics, Inc.
  • Johnson & Johnson
  • Kineta, Inc
  • Kymab Limited
  • Merck & Co., Inc.
  • Microbiotix, Inc.
  • Micropharm Limited
  • NanoViricides, Inc.
  • Navigen Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Peregrine Pharmaceuticals, Inc.
  • Phelix Therapeutics, LLC
  • Profectus BioSciences, Inc.
  • RedHill Biopharma Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • SignPath Pharma Inc
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sirnaomics, Inc.
  • Soligenix, Inc.
  • Taiga Biotechnologies, Inc.
  • Tamir Biotechnology, Inc.
  • TGV-Laboratories
  • 富山化学工業
  • Vaxeal Holding SA
  • XBiotech USA, Inc.

エボラウイルス感染症:治療薬の評価

  • 単剤治療薬の場合
  • 併用
  • 併用治療薬の場合
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

エボラウイルス感染症治療薬:パイプライン製品の最新動向

エボラウイルス感染症治療薬:開発が休止状態の製品

エボラウイルス感染症治療薬:開発が中止された製品

エボラウイルス感染症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8001IDB

Summary

Global Markets Direct's, 'Ebola Viral Infections - Pipeline Review, H1 2016', provides an overview of the Ebola Viral Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ebola Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebola Viral Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections
  • The report reviews pipeline therapeutics for Ebola Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ebola Viral Infections therapeutics and enlists all their major and minor projects
  • The report assesses Ebola Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ebola Viral Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Ebola Viral Infections Overview
  • Therapeutics Development
  • Ebola Viral Infections - Therapeutics under Development by Companies
  • Ebola Viral Infections - Therapeutics under Investigation by Universities/Institutes
  • Ebola Viral Infections - Pipeline Products Glance
  • Ebola Viral Infections - Products under Development by Companies
  • Ebola Viral Infections - Products under Investigation by Universities/Institutes
  • Ebola Viral Infections - Companies Involved in Therapeutics Development
  • Ebola Viral Infections - Therapeutics Assessment
  • Drug Profiles
  • Ebola Viral Infections - Recent Pipeline Updates
  • Ebola Viral Infections - Dormant Projects
  • Ebola Viral Infections - Discontinued Products
  • Ebola Viral Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ebola Viral Infections, H1 2016
  • Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Ebola Viral Infections - Pipeline by Abivax S.A., H1 2016
  • Ebola Viral Infections - Pipeline by AnGes MG, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by ANP Technologies, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Avipero Limited, H1 2016
  • Ebola Viral Infections - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by BioFactura, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Celgene Corporation, H1 2016
  • Ebola Viral Infections - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Enyo Pharma S.A.S., H1 2016
  • Ebola Viral Infections - Pipeline by Etubics Corporation, H1 2016
  • Ebola Viral Infections - Pipeline by GeoVax Labs, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Gilead Sciences, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Ebola Viral Infections - Pipeline by Globavir Biosciences, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Hemispherx Biopharma, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Humabs BioMed SA, H1 2016
  • Ebola Viral Infections - Pipeline by Immune Response BioPharma, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Immunovaccine, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Integrated BioTherapeutics, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Johnson & Johnson, H1 2016
  • Ebola Viral Infections - Pipeline by Kineta, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Kymab Limited, H1 2016
  • Ebola Viral Infections - Pipeline by Merck & Co., Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Microbiotix, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Micropharm Limited, H1 2016
  • Ebola Viral Infections - Pipeline by NanoViricides, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Novavax, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Phelix Therapeutics, LLC, H1 2016
  • Ebola Viral Infections - Pipeline by Profectus BioSciences, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Ebola Viral Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by SignPath Pharma Inc, H1 2016
  • Ebola Viral Infections - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Ebola Viral Infections - Pipeline by Sirnaomics, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Soligenix, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Taiga Biotechnologies, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by Tamir Biotechnology, Inc., H1 2016
  • Ebola Viral Infections - Pipeline by TGV-Laboratories, H1 2016
  • Ebola Viral Infections - Pipeline by Toyama Chemical Co., Ltd., H1 2016
  • Ebola Viral Infections - Pipeline by Vaxeal Holding SA, H1 2016
  • Ebola Viral Infections - Pipeline by XBiotech USA, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Ebola Viral Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Ebola Viral Infections - Dormant Projects, H1 2016
  • Ebola Viral Infections - Dormant Projects (Contd..1), H1 2016
  • Ebola Viral Infections - Dormant Projects (Contd..2), H1 2016
  • Ebola Viral Infections - Dormant Projects (Contd..3), H1 2016
  • Ebola Viral Infections - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Ebola Viral Infections, H1 2016
  • Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top